research:bisphosphonates_and_hip_fracture
Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
|
research:bisphosphonates_and_hip_fracture [2017/03/24 18:16] marc_suchard created |
research:bisphosphonates_and_hip_fracture [2017/12/14 05:54] (current) schuemie |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Comparative effectiveness of alendronate and risedronate in reducing the risk of hip fracture ====== | + | ====== Comparative effectiveness of alendronate and raloxifene in reducing the risk of hip fracture ====== |
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** To compare the effectiveness in reducing the risk of hip fracture between alendronate and risedronate. | + | **Objective:** To compare the effectiveness in reducing the risk of hip fracture between alendronate and raloxifene. |
| **Rationale:** Osteoporosis is characterized by decreased bone mass and deterioration of bone tissue, resulting in reduced bone strength and increased fracture risk. Approved therapies for osteoporosis include bisphosphonates, calcitonin, raloxifene and teriparatide. Among these drugs, alendronate and raloxifene are the most popular osteoporosis medication and a burden of prescription are performed annually. | **Rationale:** Osteoporosis is characterized by decreased bone mass and deterioration of bone tissue, resulting in reduced bone strength and increased fracture risk. Approved therapies for osteoporosis include bisphosphonates, calcitonin, raloxifene and teriparatide. Among these drugs, alendronate and raloxifene are the most popular osteoporosis medication and a burden of prescription are performed annually. | ||
| Line 20: | Line 20: | ||
| ** Additional Participants:** Jon Duke; George Hripcsak; David Madigan; Christian Reich; Patrick Ryan; Martijn Schuemie; | ** Additional Participants:** Jon Duke; George Hripcsak; David Madigan; Christian Reich; Patrick Ryan; Martijn Schuemie; | ||
| - | **Full Protocol:** //<coming soon>// | + | **Full Protocol:** [[https://github.com/OHDSI/StudyProtocols/blob/master/AlendronateVsRaloxifene/extras/alendronate_raloxifene_hip_fracture.docx?raw=true|Protocol]] |
| **Initial Proposal Date:** March 21, 2017 | **Initial Proposal Date:** March 21, 2017 | ||
| Line 31: | Line 31: | ||
| </WRAP> | </WRAP> | ||
| - | |||
| ===== Requirements ===== | ===== Requirements ===== | ||
| **CDM:** V5 | **CDM:** V5 | ||
| Line 42: | Line 41: | ||
| ===== Code ===== | ===== Code ===== | ||
| - | [[https://github.com/OHDSI/StudyProtocols]] | + | [[https://github.com/OHDSI/StudyProtocols/tree/master/AlendronateVsRaloxifene]] |
| ===== Discussion ===== | ===== Discussion ===== | ||
research/bisphosphonates_and_hip_fracture.1490379384.txt.gz · Last modified: 2017/03/24 18:16 (external edit)
Page Tools
